Interestingly, in the GHAS trial, we also found a parallel and significant increase of VEGFA-R2 or KDR/flk-1 mRNA levels from muscle samples in the GH group (group A) compared to the placebo group (group B) (Figure 6A), which confirmed the action of VEGFA, a finding consistent to that from animal models of hindlimb ischemia treated with the IGF-I plasmid [133]. Here, GH1 is linked to ischemia.